Is Ventyx Biosciences, Inc. (VTYX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.1% / 30% | 21.6% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 1.1% / 33% | 21.6% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 3.9% / 33% | 78.6% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 1.1% / 33% | 21.6% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 3.9% / 33% | 78.6% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -45.4% | |
| Return on Assets (ROA) | -28.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$131M |
| Free Cash Flow | -$131M |
| Total Debt | $11M |
| Debt-to-Equity | 5.2 |
| Current Ratio | 17.9 |
| Total Assets | $277M |
Price & Trading
| Last Close | $14.00 |
| 50-Day MA | $13.23 |
| 200-Day MA | $6.78 |
| Avg Volume | 3.6M |
| Beta | 1.3 |
|
52-Week Range
$0.78
| |
About Ventyx Biosciences, Inc. (VTYX)
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its pipeline includes small molecule therapeutics to treat inflammation across cardiometabolic disorders, neurodegenerative diseases, and inflammatory disorders. The company's portfolio of NLRP3 inhibitors includes VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor that is in a Phase 2a trial for patients with early Parkinson's disease and is in a Phase 2 trial for patients with obesity and additional risk factors for cardiovascular disease. Ventyx Biosciences, Inc. was incorporated in 2018 and is headquartered in San Diego, California. As of March 4, 2026, Ventyx Biosciences, Inc. operates as a subsidiary of Eli Lilly and Company.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Ventyx Biosciences, Inc. (VTYX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Ventyx Biosciences, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Ventyx Biosciences, Inc.'s debt ratio?
Ventyx Biosciences, Inc.'s debt ratio is 1.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 3.9%.
What are Ventyx Biosciences, Inc.'s key financial metrics?
Ventyx Biosciences, Inc. has a market capitalization of $1.0B. Return on equity stands at -45.4%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.